As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity for weight loss, doctors are observing a ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil ...
Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...
GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...
Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...
The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...